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Oral mucosa is a useful material for regeneration therapy with the advantages of its accessibility and versatility regardless of age
and gender. However, little is known about the molecular characteristics of oral mucosa. Here we report the first comparative
profiles of the gene signatures of human oral mucosa fibroblasts (hOFs), human dermal fibroblasts (hDFs), and hOF-derived
induced pluripotent stem cells (hOF-iPSCs), linking these with biological roles by functional annotation and pathway analyses.
As a common feature of fibroblasts, both hOFs and hDFs expressed glycolipid metabolism-related genes at higher levels compared
with hOF-iPSCs. Distinct characteristics of hOFs compared with hDFs included a high expression of glycoprotein genes, involved
in signaling, extracellular matrix, membrane, and receptor proteins, besides a low expression of HOX genes, the hDFs-markers.
The results of the pathway analyses indicated that tissue-reconstructive, proliferative, and signaling pathways are active, whereas
senescence-related genes in p53 pathway are inactive in hOFs. Furthermore, more than half of hOF-specific genes were similarly
expressed to those of hOF-iPSC genes and might be controlled by WNT signaling. Our findings demonstrated that hOFs have
unique cellular characteristics in specificity and plasticity. These data may provide useful insight into application of oral fibroblasts
for direct reprograming.
1. Introduction
Oral mucosa is a convenient cell source for regenerative
medicine, having the following advantages: (1) simple oper-
ation, (2) no cosmetic and functional problems after opera-
tion, (3) fast wound healing without scar formation [1], (4)
nonkeratinizing epithelia, and (5) no need to consider age
and gender differences. Practically, epithelial cell-sheets of
human oral mucosa have been used as the grafting material
for corneal and esophageal mucosal reconstructions after
surgically removing damaged mucosal tissue in regeneration
therapy [2, 3]. However, few studies have focused on human
oral mucosa fibroblasts (hOFs) as material for regenerative
medicine, and little is known about the molecular basis of
their characteristics.
Recently, induced pluripotent stem cell (iPSC) technol-
ogy has shown remarkable progress and has been applied to
personalized medicine for diagnostics, drug screening, and
regenerative therapy [4]. We also generated human iPSCs
from oral mucosa fibroblasts (hOFs-iPSCs), and the excised
area of the buccal mucosa was completely healed within a
week without any scar formation, as expected [5]. So far,
scarless healing is well recognized in fetal, but not adult skin
[6]. Therefore, molecular events of the healing process have
been studied by comparing postnatal (adult) and fetal skin
tissues [7–12].The differences between fetal and adult healing
are strongly related to the production of inflammatory-
triggered extracellular matrix (ECM), activation of growth
factor signaling, and induction of epithelial-mesenchymal
transition (EMT) [1, 10–12]. For example, fibronectin, type
III collagen, and hyaluronic acid are more abundant in the
fetal skin than in adult skin [1, 8, 11, 13–15]. Furthermore,
antifibrotic tumor growth factor-beta3 (TGF-beta3) is highly
expressed during fetal wound healing, whereas profibrotic
TGF-beta1 and TGF-beta2 are low or absent [1, 7, 11]. These
results suggest that skin fibroblasts are deeply involved in
ECM deposition and remodeling. In the case of hOFs, higher
activity of matrix metalloproteinase-2 (MMP-2) combined
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with decreased production and activation of tissue inhibitors
of metalloproteinases have been demonstrated by comparing
hOFs with skin fibroblasts during ECM remodeling [14].
So far, two comprehensive transcriptome studies have
been reported using oral mucosa. One included the com-
parison of the expression profiles between skin and oral
mucosal tissue derived from wound healing mouse models
[16]. In this report, oral mucosa epithelial cells produced far
less amounts of proinflammatory cytokines compared with
skin epithelial cells. The other study compared cultured age-
matched human skin fibroblasts with hOFs, showing that
wounding stimuli induced cell proliferation and reorganiza-
tion of collagenous environments in hOFs to a greater extent
than in skin fibroblasts [17]. Based on these previous studies,
we hypothesized that the sensitivity and plasticity of hOFs
may explain their uniqueness and hiPSCs can be used as
the alternative for fetal skin fibroblasts to compare the gene
profiles.
Additionally, we previously found that endogenous
Kru¨ppel-like factor 4 (KLF4) and v-myc avian myelocytoma-
tosis viral oncogene homolog (c-MYC), which are the repro-
gramming factors for generating iPSCs, and maternally
expressed gene 3 (MEG3), which is an imprinted gene and
long noncoding RNA, were highly expressed in hOFs [5].
Meg3/Gtl2 is located within the delta-like 1 homolog 1 (Dlk1)-
deiodinase, iodothyronine type III (Dio3) region and the
activation of this region is associated with the level of
pluripotency in iPSCs or ESCs [18]. These findings may
exhibit a part of plasticity in hOFs.
In this study, we performed comparative analyses of gene
profiles of hOFs, hDFs, and hOF-iPSCs to understand the
molecular characteristics of hOFs. We chose hOFs derived
from the buccal region, not other regions of oralmucosa (gin-
giva, palate, and tongue) because of its superior accessibility
as a cell source appropriate for future regenerative medicine.
hOF-iPSCs were used as not only the alternative for fetal
skin fibroblasts, but also pluripotent stem cells to find out the
specificity in the gene signature of hOFs.
2. Materials and Methods
2.1. Human Fibroblasts. hOFs were isolated from individ-
ually collected buccal mucosal tissues obtained from four
healthy volunteers (26–35 years old) after receiving written
agreement including an informed consent at the Tokushima
University Medical and Dental Hospital. Approval from the
Institutional Research Ethics Committee of the University
of Tokushima was obtained (Project number 708). Details
on hOFs isolation have been described previously [5]. After
isolation, hOFs were individually designated as hOF1 to
hOF4. Among them, we failed to establish primary cell
culture from hOF1, so we used three successful cell lines,
hOF2, hOF3, and hOF4, for further experiments.
hOFs (hOF2, hOF3, and hOF4) were cultured in Dul-
becco’s Modified Eagle Medium (DMEM; Nissui, Tokyo,
Japan) supplemented with 10% FBS (Nichirei Biosciences,
Tokyo, Japan). Three types of hDFs derived from individuals
aged 33–36 years old were purchased from the Health
Science Research Resources Bank (TIG110, TIG111, and
TIG114; Osaka, Japan). hDFs were cultured in Eagle’s MEM
(EMEM; Nissui) supplemented with 10% FBS (Nichirei Bio-
sciences).
2.2. Generation of hOF-iPSCs. hOF-iPSCs were generated as
shown previously [5]. Briefly, mouse solute carrier family 7,
member 1 (mslc7a1), was introduced into hOFs using lentiviral
infection. Then, four reprogramming factors, POU class 5
homeobox 1/octamer-binding transcription factor 4 (POU5F1/
OCT4), KLF4, SRY (sex determining region Y)-box 2 (SOX2),
and v-myc avian myelocytomatosis viral oncogene homolog
c-MYC, were transduced by retroviral infection. Generated
hOF-iPSCs were maintained in human ES medium (Repro-
CELL, Tokyo, Japan) supplemented with 5 ng/mL of basic
fibroblast growth factor (bFGF) on SNL feeder cells. The
pluripotency of hOF-iPSCs was confirmed by the expression
of the pluripotent cell markers and by in vitro differentiation
through embryoid body formation.
2.3. RNA Isolation. RNA samples were prepared from three
individual samples in each group (hOFs, hDFs, and hOF-
iPSCs; a total of nine samples). Total RNA was isolated using
TRI Reagent (Molecular Research Center, Cincinnati, OH,
USA), according to the manufacturer’s protocol.
2.4. Microarray Analyses. Microarray analysis was per-
formed as previously described [19]. In brief, GeneChip
Human Gene 1.0 ST Arrays (Affymetrix, Santa Clara, CA,
USA) containing 28,869 oligonucleotide probes for known
and unknown genes were used to define gene signatures.
First-strand cDNAwas synthesized with 400 ng of total RNA
from hOFs and hDFs or with 220 ng from hOFs-iPSCs using
a WT Expression Kit (Affymetrix), according to the man-
ufacturer’s instructions, modified with additional ethanol
precipitation. With cRNA obtained from the first-strand
cDNA, the second-cycle cDNA reaction was performed.
Resulting cDNA was end-labeled with a GeneChip WT
Terminal Labeling Kit (Affymetrix). Approximately 5.5 𝜇g of
labeled DNA target was hybridized to the array for 17 h at
45∘Con theGeneChipHybridizationOven 640 (Affymetrix).
After washing, arrays were stained on a GeneChip Fluidics
Station 450 and scanned with a GeneChip Scanner 3000 7G
(Affymetrix). A CEL file was generated for each array. All
microarray data from the three groups (nine samples in total)
have been deposited in Gene expression Omnibus (GEO,
http://www.ncbi.nlm.nih.gov/geo/) under GEO Accession
number GSE56805.
2.5. In Silico Data Analyses. The data were analyzed with
GeneSpring GX12.0 (Agilent Technologies, Santa Clara, CA,
USA). The normalization and summarization of CEL files
were performed by “Exon RMA 16” algorithm. After that,
the signal values of probe sets were transformed to the value
of log
2.
For the technological variability, we checked several
quality controls including Hybridization Controls (provided
byAffymetrix), Histogram, Profile Plot,Matrix Plot, 3DPCA,
Pearson’s correlation coefficient, and hierarchical clustering
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analyses following the standard protocols provided by the
manufacturers. Among them, the results of Hybridization
controls and Pearson’s correlation coefficient were shown in
Supplementary Figures S1B and S1C in Supplementary Mate-
rials available online at http://dx.doi.org/10.1155/2015/121575,
respectively. Each value of Pearson’s correlation coefficient is
indicated as follows: 1 indicates perfect positive correlation
between two samples, 0.80 to 1.0 indicates very strong correla-
tion, and 0.60 to 0.79 indicates strong correlation. Expressed
genes that showed a fluorescence intensity greater than 100
were further analyzed. Average gene expression level was
calculated for three samples in each group and used for the
comparison. To make the stringent criteria, several statistical
analyses were performed. First, the data obtained from
the differently expressed genes between the 2 groups were
analyzed by one-way ANOVA and cut off with the corrected
𝑝-value (𝑝 < 0.05) according to Benjamini-Hochberg (BH)
method. Furthermore, Tukey’s honestly significant difference
(HSD) test was used as the post hoc test, and the differently
expressed genes between the 2 groups were extracted. Among
28,869 gene probes, 12,713 gene probes were left after one-
way ANOVA and BH analyses (all data was 𝑝 < 0.05,
Supplementary Table S1). From these 12,713 gene probes,
more than 2-fold differentially expressed gene probes were
selected between the two paired groups.
Functional analyses were performed using the Database
for Annotation, Visualization and Integrated Discovery
(DAVID) v6.7 (http://david.abcc.ncifcrf.gov/) [20, 21]. Major
biological significance and importance were evaluated by
functional annotation clustering (FAC) tool in DAVID. To
obtain enrichment clusters of functionally significant and
important genes, FAC analysis was performed with the
enrichment scores below medium stringency. Pathway anal-
yses were conducted using Kyoto Encyclopedia of Genes
and Genomes (KEGG, http://www.genome.jp/kegg/) path-
way tools.
3. Results
3.1. Gene Profiles of Microarray Data. To analyze the molecu-
lar profile of hOFs, we prepared three types of cells, hOFs,
hDFs, and hOF-iPSCs. Three independent cell lines from
different donors were chosen to obtain accurate results from
each cell type. Heat map and hierarchical clustering analysis
revealed that the gene expression pattern in each group was
conserved, except for hDF3 (TIG114) and hOF4, for which
intermediate patterns between fibroblasts and hOF-iPSCs
were identified (Figure 1(a)). Notably, 56% of probes were
expressed at the similar levels (16,156 out of 28,869 probes;
less than 2-fold difference) among hOFs, hDFs, and OF-
iPSCs. While our samples were not exact age- and gender-
matched samples, we observed the strong correlation among
the samples by Pearson’s correlation coefficient analysis (Sup-
plementary Figure S1A). Each correlation coefficient value
among the samples in each group, and also that between
hOFs and hDFs, was within the range between 0.9 and
1.0. Furthermore, each correlation coefficient value between
either hOFs or hDFs and hOF-iPSCs was within the range
between 0.7 and 0.8. These results indicated that our data
may, at least in part, exclude the issues about age and gender
difference with the strong correlation among the samples.
The reliability of microarray hybridization techniques were
confirmed by the company-supplied hybrydization control
(Figure S1B).
Next, average gene expression signal values in each
group were calculated and used for further comparative
analyses. Figure S1C shows the scattered plot of gene profile
comparison between hOFs and hDFs. Each gene expression
of samples was indicated as a spot, and most of them were
exhibited within 2-fold line (green line).Therefore, threshold
can be set at 2-fold to find the difference of gene expression
profile between hOFs and hDFs.
Out of 12,713 probes, we found that 5,738 probes and 5,672
probes (45%) were more than 2-fold differently expressed
in hOFs and hDFs, respectively, compared with those in
hOF-iPSCs (Figure 1(b), upper panel, left). Approximately
2,300 probes were highly expressed, whereas the expression
of 3,400 probes was lower in both hOFs and hDFs than
in hiPSCs (Figure 1(b), lower panel). In contrast, only 3.4%
(434/12,713 probes) of differentially expressed probes were
observed between hOFs and hDFs (Figure 1(b), upper, right).
Among these, 272 probes had a high expression and 162
probes had a low expression in hOFs compared with the
expression in hDFs (Figure 1(b), upper panel, right).
3.2. Enriched Pathways in Fibroblasts. At the beginning, we
confirmed the expression levels of several embryonic stem
cells (ESCs) markers and reprogramming factors that had
been generally observed in iPSCs (Figure 2(a)). As expected,
hOF-iPSCs highly expressed all pluripotent markers tested
for, that is, micro RNA302a (MIR302A), MIR302B, lin-28
homolog A (LIN28A), Nanog homeobox (NANOG), develop-
mental pluripotency associated 4 (DPPA4), glypican 4 (GPC4),
prominin 1 (PROM1), growth differentiation factor 3 (GDF3),
POU5F1/OCT4, and SOX2. We also found that the repro-
gramming factors KLF4 and c-MYC were highly expressed
in hOFs and hDFs than in hOF-iPSCs. These results were
consistent with previous observations [5].
To elucidate the characteristics of hOFs, we first com-
pared the gene profiles of fibroblasts (hOFs or hDFs) with
hOF-iPSCs in steady-state condition. For prediction of the
biological function of respective gene profiles, we matched
functionally related gene groups to the known pathways by
pathway analysis using DAVID linked with KEGG. Genes
in thirty pathways were expressed at lower levels in hOFs
and hDFs than in hOF-iPSCs, suggesting that these pathways
are functionally active in hOF-iPSCs (Figure 2(b)). High
expression groups in hOF-iPSCs represented pathways of
energy metabolism (glycolysis and tricarboxylic acid (TCA)
cycle), nucleotidemetabolism (DNA replication, DNA repair,
and spliceosome), cell cyclemetabolism, andmembrane lipid
metabolism (Figure 2(b) and Supplementary Figure S2).
Conversely, 46 pathways were enriched among the highly
expressed genes in hOFs and hDFs compared with those
in hOF-iPSCs (Figure 2(c)). We found that the pathways
of glycosaminoglycan (GAG) degradation, glycosphingolipid
(GSL) biosynthesis, keratan and heparan sulfate biosynthesis,
and lysosome metabolism were highly enriched in hOFs
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Figure 1: Gene expression signatures in hOFs, hDFs, and hOF-iPSCs. (a) Heat map and hierarchical clustering of whole microarray probes
for each of the nine samples. Three individual samples were prepared from each of three types of cells, hOFs, hDFs, and hOF-iPSCs. (b)
Comparisons of average signal values among the three types of cells, hOFs, hDFs, and hOF-iPSCs. The number indicates differentially
expressed genes (𝑝 < 0.05, ≥2-fold change; upper panel, left). Scatter plots comparing the average signal values of three samples are shown
and the number of differentially expressed probes at more than 2-fold levels is indicated as follows: hOFs versus hDFs (upper panel, right),
hOFs versus hOF-iPSCs (lower panel, left), and hDFs versus hOF-iPSCs (lower panel, right).
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Pathways
Enrichment score
hOFs hDFs
Glycosaminoglycan degradation 4.1 4.8
Glycosphingolipid biosynthesis 3.7 3.6
Bladder cancer 3.5 3.2
Keratan sulfate biosynthesis 3.1 3.2
Chondroitin sulfate biosynthesis 2.9
Heparan sulfate biosynthesis 2.8
Other glycan degradation 2.8
ECM-receptor interaction 2.9 3.4
Pancreatic cancer 2.7 2.6
Lysosome 2.6 2.6
Complement and coagulation cascades 2.5 2.4
mTOR signaling pathway 2.5 2.3
Focal adhesion 2.4 2.7
Melanoma 2.3 2.2
Chronic myeloid leukemia 2.3 2.2
Non-small-cell lung cancer 2.2 2.2
Axon guidance 2.1 1.8
Renal cell carcinoma 2.1 1.8
Acute myeloid leukemia 2.1 2.0
Dilated cardiomyopathy 2.0 2.5
TGF-beta signaling pathway 2.1
Colorectal cancer 1.9 2.1
Intestinal immune network for IgA 
production
1.9
Arrhythmogenic right ventricular 
cardiomyopathy (ARVC)
1.8
VEGF signaling pathway 1.8 1.8
Glioma 1.8 1.9
Pathways in cancer 1.7 1.6
Hypertrophic cardiomyopathy (HCM) 1.7 2.1
Adipocytokine signaling pathway 1.7
PPAR signaling pathway 1.7
Melanogenesis 1.7 1.6
Vascular smooth muscle contraction 1.7 1.8
GnRH signaling pathway 1.7 1.7
Prostate cancer 1.6 1.8
Gap junction 1.6 1.8
MAPK signaling pathway 1.6 1.7
B cell receptor signaling pathway 1.6
Progesterone-mediated oocyte maturation 1.7
Fc gamma R-mediated phagocytosis 1.6
Apoptosis 1.6 1.6
Calcium signaling pathway 1.5 1.4
Toll-like receptor signaling pathway 1.5
Regulation of actin cytoskeleton 1.5 1.6
Cytokine-cytokine receptor interaction 1.3 1.5
Purine metabolism 1.4
Endocytosis 1.4
Pathways
Enrichment score
hOFs hDFs
DNA replication 4.7 4.2
Mismatch repair 4.6 4.0
One carbon pool by folate 4.1 4.1
Homologous recombination 3.5 3.3
Spliceosome 3.3 3.0
Cell cycle 3.2 3.1
Nonhomologous end-joining 3 3.6
Base excision repair 2.8 2.5
RNA degradation 2.8 2.5
Aldosterone-regulated sodium reabsorption 2.4 1.8
Proteasome 2.4 2.2
Basal transcription factors 2.3 2.3
Glycosphingolipid biosynthesis 2.1
Cysteine and methionine metabolism 2.1 2.1
Propanoate metabolism 2.1 2.1
Valine, leucine, and isoleucine degradation 2.1 2.1
Progesterone-mediated oocyte maturation 2.1 2.2
Citrate cycle (TCA cycle) 1.9
Nucleotide excision repair 2.1 1.8
Oocyte meiosis 2 1.8
Pyrimidine metabolism 1.9 1.7
Glycine, serine, and threonine metabolism 1.9
Aminoacyl-tRNA biosynthesis 1.8 1.8
p53 signaling pathway 1.8 1.9
Pyruvate metabolism 1.8
Systemic lupus erythematosus 1.7 1.5
Purine metabolism 1.6 1.6
Tight junction 1.5 1.5
Ubiquitin-mediated proteolysis 1.4 1.5
Colorectal cancer 1.5
Gene hOFs hDFs hiPSCs
MIR302B 22.6 22.8 2,572.0
MIR302A 23.0 23.1 2,173.7
LIN28A 96.0 97.1 7,916.2
NANOG 79.9 77.9 4,640.8
DPPA4 57.1 53.5 3,322.3
GPC4 170.5 230.7 2,070.6
PROM1 46.2 41.6 1,060.1
GDF3 56.9 58.8 353.1
POU5F1
(OCT4) 139.7 136.9 6,721.7
SOX2 86.8 88.0 4,183.4
KLF4 402.1 374.6 155.5
c-MYC 899.3 1211.8 966.5
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Figure 2: Continued.
6 BioMed Research International
Lc3cer
B3GNT5
Lc4cer
nLc4Cer
B4GALT4
B3GALT1/5
sLc4Cer
LNF III cer 
(SSEA-1)
FUT9
snLc4Cer
ST3GAL6
nLc5Cer
B3GNT2
nLc6Cer
B4GALT4
VI3NeuAc-nLc6Cer
III3Fuc-nLc6Cer
FUT9 GCNT2 B3GNT2
nLc7Cer
Lacto/neolacto-series
ST3GAL6
Lactosylceramide
iso-nLc8Cer
B4GALNT1
GT3
GT2
GT1c
GM3
GM2
GM1a
GD1a
GD3
GD2
GD1b
GT1b
Lactosylceramide
Asialo
GM2
GM1b
Asialo
GM1
B4GALNT1
B4GALNT1B4GALNT1
B3GALT4
B3GALT4
B3GALT4B3GALT4
ST3GAL1/2 ST3GAL1/2 ST3GAL1/2
ST6
GALNAC6
ST6
GALNAC6
ST6
GALNAC6
HEXA
GLB1
Ganglio-series
Gb3cer
Gb4cer
Gb5cer
(SSEA-3)
V3NeuAc-Gb5Cer
(SSEA-4)
A4GALT
HEXA
IV3GalNAca-Gb4Cer
GBGT1
NAGA
ST3GAL1/2
Globo-series
B3GALT5
(d)
GT1a𝛼 GQ1b𝛼GD1𝛼
Figure 2: Continued.
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Genes Description hOFs hDFs hOF-iPSCs
hOF-iPSCs
hOF-iPSCs
B3GALT4 UDP-Gal: betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 4 310.9 230.4 155.1
B4GALNT1 Beta-1,4-N-acetyl-galactosaminyl transferase 1 312.1 287.7 120.7
GLB1 Galactosidase, beta 1 2,660.3 2,522.1 1,254.7
HEXA Hexosaminidase A (alpha polypeptide) 2,023.9 1,693.8 495.3
ST3GAL1 ST3 beta-galactoside alpha-2,3-sialyltransferase 1 852.1 824.4 109.5
ST3GAL2 ST3 beta-galactoside alpha-2,3-sialyltransferase 2 875.9 907.3 435.1
ST6GALNAC6 ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-
1,3)-N-acetylgalactosaminidealpha-2,6-sialyltransferase 6
2,503.2 2,211.2 763.1
Genes Description hOFs hDFs
A4GALT Alpha 1,4-galactosyltransferase 683.2 510.6 178.5
GBGT1 Globoside alpha-1,3-N-acetylgalactosaminyltransferase 1 572.8 362.6 198.1
HEXA Hexosaminidase A (alpha polypeptide) 2,023.9 1,693.8 495.3
NAGA N-acetylgalactosaminidase, alpha- 1,278.8 852.6 388.3
ST3GAL1 ST3 beta-galactoside alpha-2,3-sialyltransferase 1 852.1 824.4 109.5
ST3GAL2 ST3 beta-galactoside alpha-2,3-sialyltransferase 2 875.9 907.3 435.1
Genes Description hOFs hDFs
B3GNT2 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2 97.9 105.8 686.1
B3GALT1 UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 1 44.3 37.6 1,548.3
B3GALT5 UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 5 55.3 57.9 171.7
ST3GAL6 ST3 beta-galactoside alpha-2,3-sialyltransferase 6 47.5 48.9 201.2
B3GNT5 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 5 53.5 45.0 217.8
B4GALT4 UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase, 
polypeptide 4
142.0 168.0 362.3
GCNT2 enzyme (I blood group) 43.1 44.2 475.2
FUT9 Fucosyltransferase 9 (alpha (1,3) fucosyltransferase) 30.9 32.5 64.4
Glycosphingolipid biosynthesis (globo-series) 
Glycosphingolipid biosynthesis (ganglio-series) 
Glycosphingolipid biosynthesis (lacto/neolacto-series) 
(e)
Glucosaminyl (N-acetyl) transferase 2, I-branching
Figure 2: Pathway analysis of human fibroblasts and hOF-iPSCs. (a) Gene expression of ESCs markers and reprogramming factors. The
numbers indicate average signal values in each cell type. Red: highly expressed genes in hOFs and hDFs compared with hiPSCs. (b) and
(c) Pathways with low (b) and high (c) expression in human fibroblasts compared with those in hOF-iPSCs. Numbers indicate enrichment
scores provided byDAVID.The top three clusters are colored. Blanks indicate “not listed” in the samples.The top three clusters are highlighted
in blue (b) and in red (c), respectively. (d) A diagram of various GSL-biosynthetic pathways. Red and blue colors indicate genes with high
and low expressions in human fibroblasts, respectively. cer: ceramide; Gb with subscript: globoside with the number of carbohydrates; G
with subscript: ganglioside with subclass; Lc with subscript: lacto- with the number of carbohydrates; nLc-: neolacto-; Fuc: fucose; GalNAc:
N-acetylgalactosamine; NeuAc: N-acetylneuraminic acid. (e) Individual gene-expression levels of each GSL-biosynthetic pathway in hOFs,
hDFs, and hOF-iPSCs. Red and Blue indicate the same as in (d).
and hDFs. Among them, glycosyltransferases (GTases) in
the globo- and ganglio-series of GSL biosynthesis pathways,
but not GTases in the lacto- or neolacto-series of the GSL
synthetic pathway, were highly expressed in hOFs and hDFs
(Figures 2(d) and 2(e)). In addition to these, other signaling
components, such as ECM-receptor interaction, complement
and coagulation, mammalian target of rapamycin (mTOR)
signaling pathway, focal adhesion, and signaling pathways
of TGF-beta, mitogen-activated protein kinase (MAPK),
vascular endothelial growth factor (VEGF), and calciumwere
enriched to a greater extent in hOFs and hDFs than in hOF-
iPSCs (Figure 2(c)).
3.3. Characterization of hOFs in Comparison with hDFs.
Since some of the expressed genes in both hOFs and hDFs
must be shared in the biological pathways to display “fibrob-
lastic” characteristics comparedwith those expressed in hOF-
iPSCs, we next tried to elucidate the specificity between
hOFs and hDFs. For this purpose, we analyzed a number
of genes that were differentially expressed between hOFs
and hDFs using microarray analysis, for which overlapping
probes were designed and arranged within the same gene to
obtain accurate results. Compared with hDFs, 232 genes were
overexpressed in hOFs “hOFs > hDFs,” whereas 152 genes
were underexpressed “hOFs < hDFs.” Cranial neural crest
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markers especially, such as distal-less homeobox 5 (DLX5),
LIM homeobox 8 (LHX8), paired box 3 (PAX3), PAX9, and
transcription factor AP-2 alpha (TFAP2A), were expressed at
a remarkably high level in hOFs (Figure 3(a), left). On the
other hand, hDFs expressed homeobox (HOX) cluster genes
(Figure 3(a), right) to preserve their positional information as
expected [22].
To understand the biological roles of highly expressed
genes in hOFs, we performed FAC analysis using DAVID.
One hundred and five clusters in hOFs > hDFs and 64
clusters in hOFs < hDFs were observed. The top 12 clusters
are shown in Figure 3(b). The top three clusters in hOFs >
hDFs were glycoprotein (103 genes), ECM (21 genes), and
tube development/embryonic morphogenesis (32 genes). In
the glycoprotein cluster, genes related to signaling molecules,
extracellular component and matrix, membrane compo-
nents, and receptors were enriched (Figure 3(c), left), being
involved in receiving the extracellular signals. Conversely,
transcriptional regulation (20 genes), glycoprotein (63 genes),
and transcription activator activity (7 genes) were enriched in
hOFs< hDFs.Most of the genes highly enriched in the cluster
of transcriptional regulation were HOX genes (Figure 3(c),
right), which were shown in Figure 3(a).
Next, we performed pathway analysis to understand the
intracellular events in hOFs > hDFs and hOFs < hDFs. In
the group of hOFs > hDFs, eleven pathways were enriched
(Figure 3(d), Supplementary Table S2). These were catego-
rized into three groups, including (1) tissue-reconstructive
pathways (such as complement and coagulation cascades,
calcium signaling pathway, endocytosis, chemokine signal-
ing, focal adhesion, and regulation of actin cytoskeleton);
(2) differentiation pathways of cranial neural crest lin-
eages (melanogenesis, axon guidance); and (3) growth- and
differentiation-inducing factors. The third group comprised
three cancer-related pathways (basal cell carcinoma, pan-
creatic cancer, and pathway in cancer) comprising mainly
cytokines, growth factors, and signaling molecules, not
oncogenes. In addition, melanogenesis and axon guidance
pathways were only detected in hOFs, consistent with hOFs
being derived from cranial neural crest cells. In addition,
TGF-beta signaling was not enriched independently. Because
TGF-beta3 is expressed higher than TGF-beta1 and TGF-
beta2 in embryonic skin fibroblasts and opposed to adult
skin fibroblasts during wound healing [11], we analyzed TGF-
beta signaling pathway-related genes by KEGG program.
We found that TGF-beta2, SMAD2 and SMAD3 were highly
expressed, but not TGF-beta3 (data not shown).
Conversely, only three pathways (p53 signaling, ECM-
receptor, and focal adhesion pathways) were enriched in
hOFs < hDFs (Figure 3(e), Supplementary Table S3). p53 is
known as a tumor suppressor [23], and the expression of p53
itself showed no difference between hOFs and hDFs (data not
shown). However, the downstream genes, cyclin D1 (CCND1),
growth arrest and DNA-damage-inducible beta (GADD45B),
serpin peptidase inhibitor, clade E, member 1/plasminogen
activator inhibitor type 1 (SERPINE1/PAI-1), and insulin-like
growth factor binding protein 3 (IGFBP3)were downregulated
in hOFs. These molecules regulate cell cycle, DNA repair,
antiangiogenesis, and the anti-insulin-like growth factor 1
(IGF-1) pathway [23]. Tenascin C (TNC), integrin, alpha 1
(ITGA1), cartilage oligomeric matrix protein (COMP), and
ITGA6 were identified and seen to overlap in ECM-receptor
and focal adhesion pathways.
3.4. Plasticity and Specificity of hOFs. To further define the
characteristics of hOFs, gene groups in hOFs > hDFs and
hOFs < hDFs were filtered by similarity in gene-expression
level to hOF-iPSCs (Figure 4(a)).
First, we found that 58 genes in hOFs were shared with
the similar expression levels in hOF-iPSCs and with the
expression levels higher than that in hDFs (hOFs = hiPSCs >
hDFs; group G1), suggesting that the genes reflect the plas-
ticity or undifferentiated property of multipotent hOFs by
enhancement. Second, 103 genes were highly expressed in
hOFs compared with those in hDFs and hiPSCs (hOFs >
hiPSCs = hDFs; group G2). The genes in G2 were highly
expressed in hOFs butmay be kept at lowor absent expression
levels in hDFs. Therefore, it was suggested that the genes in
G2 can exhibit the specificity or differentiated property of
hOFs. Third, 70 genes in hOFs had expression levels similar
to hOF-iPSCs but were expressed at lower levels than in hDFs
(hOFs = hiPSCs < hDFs; group G3). The genes in G3 are
defined as the specificity of hDFs; however, these genes could
be also involved in the plasticity of hOFs by being suppressed.
Twenty-two genes in hOFswere expressed at lower levels than
in hDFs that showed expression levels similar to those of
hOF-iPSCs (hOFs < hDFs = hiPSCs; group G4), suggesting
specificity or differentiated property of hOFs by suppression
and, reciprocally, plasticity or undifferentiated property of
hDFs.
We further analyzed the individual components in the
G1–G4 groups, and we categorized them into seven groups,
such as ECM/secreted, membrane, receptor, enzyme, signal-
ing, transcriptional regulator, and others (Figure 4(b)). The
genes in each group are listed in Supplementary Tables S4–
S7. Based on this classification, we found that approximately
30%–40% of the genes in all groups comprised ECM/secreted
proteins, membrane proteins, and receptors/transporters,
which are highlighted in yellow color in Figure 4(b). These
molecular groups are all located at the interface between
the cell surface and the extracellular environment, and they
may function as a gate of chemical substances and signals
(Supplementary Tables S4–S7). Therefore, it is suggested that
both fibroblasts are sensitive to environmental factors or cues.
Then we observed that the transcriptional regulator
accounted for 10% in both G1 and G2, 34% in G3, and 0%
in G4, highlighted by pink color in Figure 4(b) (the gene list,
Supplementary Tables S4–S7).This finding is quite important
because transcriptional regulators can influence cell fate [24].
Figure 4(c) shows the lists of transcriptional regulators in
G1, G2, and G3. The listed genes in G2 and G3 were mostly
overlapping with the genes listed in Figures 3(b) and 3(c),
which are associated with the fibroblastic specificity of hOFs
and hDFs, respectively. The transcriptional regulators in G1
are supposed to represent the gene group related to the
plasticity of hOFs because transcription factor 7-like 1 (T-
cell specific, HMG-box)/T-cell factor-3 (TCF7L1/TCF3) and
BioMed Research International 9
Gene hOFs hDFs
Cranial 
neural crest
markers
DLX5 418.7 106.4
LHX8 735.2 68.9
PAX3 930.1 284.4
PAX9 4,117.5 102.0
TFAP2A 2,389.1 404.3
Gene hOFs hDFs 
A-P axis 
markers in 
the body
HOXA4 56.2 197.1
HOXA6 124.6 251.5
HOXA7 97.8 443.1
HOXA9 109.5 453.3
HOXB2 104.9 949.2
HOXB3 95.2 504.8
HOXB5 61.8 186.7
HOXB6 66.5 375.2
HOXB7 56.4 125.7
HOXB8 109.8 301.9
HOXB9 115.7 759.2
HOXC10 80.3 1,175.0
HOXC5 46.1 231.3
HOXC6 72.6 771.9
HOXC8 120.0 1,081.5
HOXC9 62.2 432.3
HOXD8 138.9 341.9
HOXD9 172.3 377.6
(a)
0 5 10 15
Neural crest cell
development
Membrane
Regulation of growth
Regulation of cytokine
production
Embryonic morphogenesis
Vascular development
Intracellular signaling
Response to oxygen levels
Carbohydrate binding
Tube development
Extracellular matrix
Glycoprotein
Fold enrichment
0 5 10
Enzyme inhibitor activity
Growth factor activity
Regulation of growth
Muscle organ development
Segmentation
Limb development
Cell adhesion
Differentiation
Extracellular region part
Transcription activator
activity
Glycoprotein
Transcriptional regulation
Fold enrichment
hOFs > hDFs hOFs < hDFs
(b)
Figure 3: Continued.
10 BioMed Research International
0 10 20 30 40
Cell adhesion
Defense response
Response to wounding
Calcium ion binding
G-protein coupled receptor
Regulation of cell motion
Carbohydrate binding
Receptor
Membrane
Extracellular matrix
Extracellular region
Signal
Fold enrichment Fold enrichment
0 10 20 30
Zinc finger
Regulation of
phosphorylation
Growth factor
Hemopoiesis
Epithelium development
Muscle cell
differentiation
Positive regulation of
transcription
Embryonic forelimb
morphogenesis
Axis specification
Negative regulation of
transcription
HOX9
Homeobox
(glycoprotein)
hOFs > hDFs
(transcriptional 
regulation)
hOFs < hDFs
(c)
0 2 4 6 8
Regulation of actin
cytoskeleton
Pathways in cancer
Focal adhesion
Chemokine
signaling pathway
Endocytosis
Axon guidance
Calcium signaling
pathway
Melanogenesis
Pancreatic cancer
Basal cell
carcinoma
Enrichment score 
Complement and
coagulation cascades
hOFs > hDFs
Pathways Genes
1
Complement 
and coagulation 
cascades
F10, F2R, TFPI, C3, CFD, C4A, 
BDKRB2
Calcium
signaling pathway 
EDNRA, EDNRB, ADCY9, ADRA1B, 
F2R, EGFR, PTK2B, BDKRB2, 
ADCY4, CHRM2
Endocytosis ARRB1, LDLR, F2R, EGFR, FLT1, 
DNAJC6, GRK5, EHD3
Chemokine signaling 
pathway
ARRB1, ADCY9, CXCL14, CXCL16, 
SHC3, PTK2B, GRK5, ADCY4
Focal adhesion
VTN, ITGA8, EGFR, FLT1, HGF, 
SHC3, FIGF, PGF
Regulation of actin 
cytoskeleton
IGF2, FGF18, ITGA8, F2R, EGFR, 
DIAPH3, BDKRB2, CHRM2
2
Melanogenesis
EDNRB, ADCY9, MITF, TCF7L1, 
ADCY4, WNT16
Axon guidance SEMA3F, EPHA5, SEMA3D, 
EPHB6, ROBO2, SEMA4D
3
Basal cell carcinoma BMP4, TCF7L1, PTCH1, WNT16
Pancreatic cancer TGFB2, EGFR, SMAD3, FIGF, PGF
Pathway in cancer
TCF7L1, EGFR, HGF, BMP4, 
FIGF, PPARG, PTCH1, WNT16, 
TGFB2, FGF18, MITF, SMAD3, 
PGF
(d)
Figure 3: Continued.
BioMed Research International 11
0 5 10
Focal adhesion
ECM-receptor
interaction
p53 signaling
pathway
Enrichment score 
Pathways Genes
p53 signaling 
pathway
CCND1, GADD45B, IGFBP3, 
SERPINE1
ECM-receptor 
interaction
TNC, ITGA11, COMP, ITGA6
Focal adhesion
CCND1, TNC, PDGFC, ITGA11, 
COMP, ITGA6
hOFs < hDFs
(e)
Figure 3: Comparison of gene profiles in hOFs and hDFs by functional annotation clustering (FAC) and pathway analysis. (a)The positional
signatures of hOFs and hDFs as an internal validation. Gene expression of cranial neural crest markers for hOFs (left). Gene expression of
anterior-posterior (A-P) axis markers in the body for hDFs (right). Numbers indicate the average signal values in hOFs and hDFs. (b)The top
12 clusters of FAC result in hOFs compared with hDFs. Red bar: the highest enriched cluster in hOFs > hDFs; blue bar: the highest enriched
cluster in hOFs < hDFs. (c) The top 12 clusters of FAC result in the individual components of glycoproteins and transcriptional regulation
in (b). (d) and (e) Pathway analysis results in genes with high (d) and low (e) expression in hOFs compared with hDFs. Indicated numbers
in (b) to (e) represent enrichment scores by DAVID. The number in (d) indicates the three groups categorized in the text. The full names of
each gene listed in (d) and (e) are shown in Supplementary Tables S2 and S3, respectively.
transducin-like enhancer of split 1 (E (sp1) homolog, Drosophila
Groucho) (TLE1) are involved in controlling ESCs status
by functioning as components of wingless-type MMTV
integration site family (WNT) signaling. The transcriptional
regulators in G2 are involved in the early developmental
regulation, and they are also recognized as markers of the
cranial neural crest. The transcriptional regulators in G3
are rich in HOX genes, which are involved in determining
localization and morphology.
Lastly, we surveyed expression levels of reprogramming
regulators because these can support plasticity in fibroblasts.
Compared with hOF-iPSCs, the higher expression of repro-
gramming enhancers, such as Gli-similar 1 (GLIS1), methyl-
CpG-binding domain protein 3 (MBD3), retinoic acid receptor,
gamma (RARG), and T-box 3 (TBX3), was detected in hOFs
and hDFs (Figure 4(d), Supplementary Table S8). Notably,
hOFs expressed RARG and TBX3 at the highest level among
the three types of cells. Conversely, LIN28A was expressed
only to a limited extent in hOFs and hDFs. MEG3, a human
homolog of mouse Meg3/gene trap locus 2 (Meg3/Gtl2), was
expressed at the higher level in hOFs than in hDFs and hOF-
iPSCs.
4. Discussion
In this study, we elucidated the unique characteristics of hOFs
through comparative analyses of gene expression profiles
among hOFs, hDFs, and hOF-iPSCs. In Figure 5(a), we
categorized the characteristic gene profile in hOFs that the
common fibroblastic features as observed in hOFs and hDFs
compared with hOF-iPSCs (upper box) and the specific
characteristics of “hOFs” can be demonstrated by comparing
with hDFs (lower box). Based on these findings, we developed
the possible gene network in hOFs as shown in Figure 5(b).
4.1. Unique Metabolic Pathways in Human Fibroblasts Com-
pared with iPSCs. First, we noted activated GSL metabolism
in both hOFs and hDFs compared with hOF-iPSCs (Figures
2 and 5(a)). GSLs are important for membrane organization,
signaling interface to ECM, cell-cell adhesion, and cell recog-
nition [25–27]. Furthermore, some GSLs function as sensors
in cellular differentiation and tissue patterning [27, 28]. GSLs
are basically categorized into three major groups: (1) the
ganglio-series and isoganglio-series, (2) the lacto-series and
neolacto-series, and (3) the globo-series and isoglobo-series
[25, 27]. The ganglio-series and isoganglio-series GSLs are
abundant in the brain and are also detected in ESCs of
embryoid bodies, neural lineage cells, macrophages, and B
cells. The ganglio-series GSLs are functionally involved in
cell adhesion and molecular recognition, forming the “gly-
cosynapse” [29, 30]. For example, monosialodihexosylgan-
glioside (GM3) is involved in integrin regulation, epidermal
growth factor (EGF) receptor signaling [31], and lipid raft
localization [32]. Conversely, lacto-series and neolacto-series
GSLs were originally found in erythrocytes as blood group
antigen and in tumors as Lewis X (Le𝑥) GSL antigen. Stage-
specific embryonic antigen-1 (SSEA-1), a marker for both
mouse ESCs and embryonic carcinoma cells (ECCs), is also
included in this group, and it contains Le𝑥 and mediates
homotypic adhesion related to compaction or autoaggrega-
tion [25]. Furthermore, the absence of lactotriaosylceramide
(Lc3cer) synthase, as shown in UDP-GlcNAc:betaGal beta-
1,3-N-acetylglucosaminyltransferase 5- (B3GNT5-) deficient
mice, has been reported to cause preimplantation lethality
[33] or multiple postnatal defects [34]. The globo-series
and isoglobo-series GSLs were originally found in human
erythrocytes as the major component. Both SSEA-3 and
SSEA-4 are common markers for human ESCs and iPSCs
[35, 36].
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Figure 4: Characterization of hOFs in comparison with hDFs and hOF-iPSCs. (a) Strategy to define the characteristics of hOFs. The
differentially expressed gene groups between hOFs and hDFs were rearranged by the expression similarity with hOF-iPSCs. The readout for
hOFs indicates the characteristics of hOFs. Each gene in G1–G4 is listed in Supplementary Tables S4–S7, respectively. (b)The characterization
of each gene group categorized in (a). Numbers indicate the percentage of gene numbers in the individual categories compared with total
numbers.The groups colored in yellow show the molecules receiving environmental stimuli. The groups colored in pink represent molecules
involved in controlling cell fate. (c) The list of individual transcriptional regulators found in (b). Each indicated number is the average signal
value in each cell type. (d) Expression levels of reprograming enhancers among the three cell types. Each indicated number is the average
signal value in each cell type. Red: hOFs > hDFs > hOF-iPSCs; blue: hOFs = hDFs > hOF-iPSCs.The full names of each gene listed in (d) are
shown in Supplementary Table S8.
In our profiles, GSL-related GTs in the globo-series
and ganglio-series GSL biosynthetic pathways were highly
expressed in both hOFs and hDFs compared with their
expression in hOF-iPSCs, whereas GTs in the lacto-series/
neolacto-series GSL biosynthetic pathways were less ex-
pressed (Figure 2(d)). GSL expression has been demonstrated
to be strictly controlled during bothmouse embryonic devel-
opment in vivo [25] and differentiation of human ESCs in
vitro [37, 38]. Globo-series and lacto-series of GSLs are highly
expressed in stem cells, whereas gangliosides are contained
in further differentiated cells such as embryoid bodies and
neuronal cells [37, 38]. Based on these findings, it is suggested
that both hOFs and hDFs have the characteristics of differen-
tiated cells except for the high expression of GTs in the globo-
series. However, we found that UDP-Gal:betaGlcNAc beta
1,3-galactosyltransferase, polypeptide 5 (B3GALT5), which cat-
alyzes the conversion from globotetraosylceramide (Gb4cer)
to globopentaosylceramide (Gb5cer) (Figures 2(d) and 2(e)),
was lower expressed in both hOFs and hDFs than in hOF-
iPSCs. Lower expression of B3GALT5may cause the accumu-
lation of Gb4cer or globotriaosylceramide (Gb3cer). Because
Gb3cer and other glycosphingolipids are also involved in
caveolar-1 oligomerization [39], their accumulation may
affect the sorting and trafficking of caveolae in themembrane,
resulting in the function of signaling in fibroblasts. Taken
together, the expression profiles of GSLs-GTs suggested their
possible roles in “the environmental sensor” in fibroblasts
through membrane metabolism.
Another unique “fibroblastic” feature is the underexpres-
sion of aerobic and anaerobic glycolysis-related genes in hOFs
and hDFs (Supplementary Figure S2). This finding suggested
that hOFs and hDFs are bioenergetically less active than hOF-
iPSCs. A recent study reported that the metabolic switching
of energy metabolism is linked with cell fate decision [40],
consistent with the change from oxidative phosphorylation
in mouse embryonic fibroblasts (MEFs) to glycolysis in
iPSCs during reprogramming [41]. In addition, it was also
demonstrated that active hypoxia inducible factor 1, alpha
subunit (HIF1𝛼), and cytochrome c oxidase (COX) could
regulate the metabolic transition from aerobic glycolysis in
mouse ESCs to anaerobic glycolysis in mouse epiblast stem
cells (EpiSCs) and human ESCs [42]. However, we observed
that expression levels ofHIF1𝛼 and COX were similar among
hOFs, hDFs, and hOF-iPSCs in our profiling data (data not
shown). Collectively, hOFs and hDFs appear to exhibit the
bioenergetically intermediate phenotype between stem cells
and terminally differentiated cells, showing the potential to
select cell fate, together with membrane sensing of GSLs.
4.2. Gene Signatures Unique to hOFs Compared with hDFs.
Next, we elucidated the differences between hOFs and
hDFs by comparative in silico analyses. The glycoprotein
group was highly enriched in hOFs compared with hDFs
(Figure 3(b), left); ECM and membrane components, cell
motion, adhesion, and defense responses, which are linked
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Figure 5: Summary of gene signatures in hOFs. (a) Overview of gene profiles in oral mucosal fibroblasts. Dotted-lined box indicates the
category of genes. Red- and blue-colored words in italics show the biological function of gene categories with high and low expressions,
respectively. (b) A proposed possible gene network in oral mucosal fibroblasts. Gene names in the different color are indicated as follows.
Red: high expression in hOFs compared with that in hDFs (hOFs > hDFs); blue: low expression in hOFs compared with that in hDFs (hOFs
< hDFs); purple: similar expression in hOFs and hDFs, but higher than hiPSCs (hOFs = hDF > hiPSCs). The box colors indicate biological
characteristics or functions as follows. Pink box: possible “plastic” characteristics; green box: possible “specific” characteristics of hOFs; gray
box: WNT signal regulators; lined box: biological function; dotted-lined box: the known key transcription factors. Dotted bar indicates
indirect effect. Detailed explanations of (a) and (b) are described in the text.
with responses to stimuli from outside the cell, were also
sequentially enriched in hOFs (Figure 3(c)). Correspond-
ing pathway analysis revealed that the pathways of tissue
reconstruction and differentiation and induction of growth
and differentiation factors were active in hOFs (Figure 3(d)).
The combination of these highly enriched groups in hOFs
may enhance the potential of responding to invasive events
or inflammation [43], the advantages of differentiating into
melanocytes and neurons (axons) [44, 45], and accessibility
of signaling molecules that maintain cell growth or differen-
tiation. These characteristics indicated that hOFs may have
the flexibility or plasticity as shown in Figure 5(a).
On the other hand, “transcriptional regulation” was
highly enriched in the underexpression group in hOFs
(Figure 3(b), right). The components of this group especially
were HOX genes, conversely representing the specificity
of hDFs. Fibroblasts derived from the various anatomical
positions in the body have been demonstrated to keep
HOX code and position-specified gene signatures to achieve
their molecular specification of site-specific variations in
fibroblasts [22]. HOX genes are known to regulate anterior-
posterior axis, patterning, and timing through development
[46]. Although both hOFs and hDFs express their positional
information, hOFs might have some plasticity due to low
expression of clusteredHOXA toHOXD groups of homeobox
genes that tightly control body axis formation (Figure 5(a)).
In addition, we found a low gene expression related
to the p53 signaling pathway in hOFs compared with
hDFs (Figure 3(e)). p53 is a tumor suppressor gene and
its activation regulates multiple events including cell cycle
arrest, apoptosis, angiogenesis and metastasis inhibition,
DNA repair, IGF-1/mTOR pathway inhibition, reprogram-
ming suppression, and cellular senescence [23, 47, 48].
Although the expression level of p53 itself was similar in
hOFs and hDFs, the downstream genes CCND1, IGFBP3,
and SERPINE1/PAI-1, which are involved in p53-induced or
stress-induced senescence [49–51], were underexpressed in
hOFs. Supportively, we confirmed that the expression of
some antisenescence regulators [52] was expressed higher
in hOFs compared to those in hDFs (Supplementary Figure
S3): klotho (KL; a membrane protein and suppressor of
aging [53]),nicotinamide phosphoribosyltransferase (NAMPT;
a converting enzyme forNAD+ biosynthesis to increase intra-
cellular NAD+ levels [54]), nuclear factor (erythroid derived 2)
related factor 2 (Nrf2; a transcription factor and induction of
antioxidant enzymes [55]), peroxisome proliferator-activated
receptor gamma (PPARG; a transcription factor, antiaging and
reduction of physiological stress [56]), PPAR delta (PPARD,
a transcription factor, inhibition of ROS generation [57]),
prion protein (PRNP; a membrane anchored glycoprotein
and antioxidant activity [58]), retinoblastoma 1 (RB1; a
tumor suppressor protein [59]), and sirtuin 1 (SIRT1; NAD+
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dependent deacetylase and a mammalian longevity protein
[60]). These findings suggested that hOFs exhibit not only
higher plasticity but also greater longevity compared to hDFs
(Figure 5(b)).
4.3. Specificity and Plasticity in hOFs Predicted by the Profiles
of Transcription Factors. We performed comparative anal-
yses between hOFs and hOF-iPSCs, which were generated
from parental hOFs (Figure 4) to elucidate hOF plasticity
and specificity. Focused on the transcription regulators that
control cell fate, we developed a plausible gene network to
characterize hOFs (Figure 5(b)).
The plasticity of hOFs could be regulated by the high
expression ofTCF7L1/TCF3 andTLE1, the negative regulators
of canonical WNT signaling. In human ESCs, canonical
WNT signaling actively regulates pluripotency. However, to
differentiate into specific cell types of mesodermal and endo-
dermal lineages, WNT signals need to be transiently down-
regulated by TCF7L1/TCF3 and TLE1 [61–66]. TCF7L1/TCF3
is also defined as a mouse ESC marker [67], and downreg-
ulation of TCF7L1/TCF3 has been observed when mouse
ESCs differentiate into EpiSCs [68]. Furthermore, Tcf7l1/Tcf3
regulates stage-specific WNT signaling during the repro-
gramming of fibroblasts into iPSCs [69], neural stem cell
status [70], or epidermal progenitor status [71]. Recently,
a new role for TCF7L1/TCF3 in skin wound healing was
reported by demonstrating that TCF7L1/TCF3 was upreg-
ulated in epithelial cells at the site of injury, accelerating
wound healing in vivo through lipocalin-2 (Lcn2) induction
[72]. Another molecule, TLE1, is a transcriptional repressor
essential in hematopoiesis and neuronal and epithelial dif-
ferentiation [73]. Recently, it was reported that TLE1 binds
to TCF3 and TCF4 but not to LEF1 and TCF1 and that
TCF-TLE1 complexes bind directly to heterochromatin in
a specific manner to control transcriptional activation [74].
Furthermore, we found that some positive regulators ofWNT
signaling were highly expressed by hOFs, for example, a
proteoglycan glypican-3 (GPC3) [75–77], a secreted proteinR-
spondin 1, 2 (RSPO1, 2) [78, 79], andWNT16 [80] (Figure 5(b),
Supplementary Tables S4 and S5). GPC3 is expressed in
pluripotent cells and cancer cells [75–77]. RSPO1 has been
demonstrated to commit to the specification of germ cells,
and RSPO2 plays a role in craniofacial, limb, and branching
development [78, 79].WNT16 is involved in the specification
of hematopoietic stem cells [80]. Taken together, the charac-
teristics of hOFs can be controlled by WNT signaling, and
our data is the first report to reveal this by transcriptome
profiles. In addition, the cranial neural crest markers were
classified into highly expressed gene group of hOFs (Figures
3(a) and 4(c)), and HOX genes were repeatedly categorized
into the underexpressed gene group of hOFs (Figures 3(b)
and 4(c)). These findings suggested that hOFs are differently
primed from dermal fibroblasts, but they preserve flexibility
or plasticity.
The specificity of hOFs is mainly characterized by
a high expression of cranial neural crest markers [44].
Forkhead box F1 (FOXF1) (lung), LIM homeobox 8 (LHX8)
(nerve), microphthalmia-associated transcription factor
(MITF) (melanogenesis), PAX9 (tooth, palate, and limb) [81],
and PPARG (adipocyte) [82, 83] are all involved in embryonic
development (Figure 5(b)). These findings suggested that
hOFs have some advantage in differentiating into neural
crest-derived lineages.
4.4. Plasticity in hOFs is Predicted by Reprogramming Regu-
lators. When we surveyed the detailed hOF gene signatures,
we found several important genes associated with plasticity.
Recent development of iPSCs technology demonstrated that
the cellular plasticity can be acquired by reprogramming
with not only four transcription factors, such as Pou5f1/Oct4,
Sox2, KLF4, and c-myc [84], but also with additional repro-
gramming regulators. Among them, we found that two
transcription factors, RARG [85] and TBX3 [86], are quite
highly expressed in hOFs compared with hDFs (Figure 4(d)).
RARG, a nuclear receptor, can form heterodimers with
nuclear receptor subfamily 5, group A,member 2/liver receptor
homolog 1 (NR5A2/LRH-1) [87], and directly activate Oct
transcription [88, 89], and the combination with reprogram-
ming factors increased reprogramming efficiency of MEFs
into mouse iPSCs [85]. Recently, Rarg and Nr5a2 combined
with achaete-scute complex homolog 1 (Ascl1), POU domain,
class 3, transcription factor 2 (Pou3f2/Brn2), and neurogenin
2 (Ngn2) enhanced the efficiency of transdifferentiation
from MEFs to functional neurons [90]. Conversely, TBX3
is necessary to maintain pluripotency of mouse ESCs and
also to regulate differentiation, proliferation, and signaling
[86, 91, 92], although TBX3 in hESC regulates proliferation
and differentiation [93]. Although the roles of RARG and
TBX3 in hOFs are not fully understood, it might be possible
for these to regulate the plasticity of hOFs (Figure 5(b)).
In the other transcription factors, GLIS1, [94] was highly
expressed, whereas NR5A2/LRH-1 was underexpressed in
both hOFs and hDFs. LIN28A, a miRNA and a repro-
gramming repressor controlling cell plasticity [95, 96], was
also expressed at quite low levels in both hOFs and hDFs.
Although MBD3, the suppression of which can increase
reprogramming efficiency [97], was highly expressed in both
hOFs and hDFs, these results suggested that both types of
fibroblasts might have a similar advantage of reprogram-
ming both cell fate and plasticity. Indeed, in hDFs, less
factors or only exogenous POU5F1/OCT4 can introduce
reprogramming [98, 99]. Furthermore, direct induction of
transdifferentiation has been reported fromhDFs to the other
cell lineage without iPSC formation [100–103]. Transdifferen-
tiation has been induced by a combination of specific media
and supplements, for example, addition of FGF2 to the cul-
ture changed transcriptional profiles in hDFs and promoted
regeneration capability [104]. Recently, it was demonstrated
that mouse DFs are not a terminally differentiated cell
type but can be further differentiated into several different
types of fibroblasts to form the dermal structure during
skin development and wound healing steps [105]. Since DFs
have the plasticity to adapt to the environmental changes
in vitro and in vivo [100–105], hOFs might have similar
properties. Further investigations are required to confirm this
hypothesis.
In addition, MEG3 was expressed at a quite high level
compared to those of hDFs and hOF-iPSCs (Figure 4(d)).
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Because MEG3 is located within the imprinted DLK1-DIO3
gene cluster on chromosome 14q32, we further examined
the additional imprinted genes (Supplementary Figure S4).
Interestingly, hOFs highly expressed both paternal imprinted
genes,DIRAS3 and IGF2, and maternal imprinted genes,H19
and MEG3, compared to those in hOF-iPSCs. Furthermore,
the expression of DLK1 and DIO3, which are paternally
expressed genes and located within the same region as
MEG3, was lower than that of MEG3 in hOFs. We found
a similar expression pattern within 14q32 in hOF-iPSCs.
MEG8, known as Rian in mouse, is also located within 14q32
andmaternally expressed, long noncoding RNAs were not on
the lists of gene profiles. The expression of DIRAS3, PEG10,
and IGF2 was reciprocally observed between hOFs and hOF-
iPSCs. Furthermore, althoughH19 and IGF2 exhibitmaternal
and paternal expressions that are located in the same region,
both genes were highly expressed in hOFs. At this moment,
we do not know the biological meaning of their expression
patterns. Further analyses will be required. MEG3 is also
known as a tumor suppressor via p53 activation [106, 107].
Because the underexpression of p53-downstream genes was
observed along with the high expression level of p53 in hOFs,
MEG3 could also be involved in the specificity of hOFs by
controlling p53 signaling as shown in Figure 5(b).
5. Conclusions
We elucidated the fibroblastic plasticity and specificity by
analyzing transcriptome profiles of GSL metabolism in hOFs
andhDFs.Theuniqueness of hOFs is defined as partly primed
cells committed to the neural crest cell lineage with plasticity
and longevity controlled by WNT and p53 gene network as
shown in Figure 5(b). Further analyses are required to prove
this hypothesis, but, importantly, our findings in the present
study provide a novel basis for discussing the potential
application of hOFs in regenerative medicine.
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